Trials / Completed
CompletedNCT01277549
Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Healthy Blood Donors
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 71 (actual)
- Sponsor
- Terumo BCT · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this protocol is to characterize the performance of CaridianBCT's Spectra Optia Apheresis System, when used to collect mononuclear cells (MNCs) and cluster of differentiation 34 (CD34) positive cells from healthy nonmobilized blood donors and healthy G-CSF (granulocyte colony stimulating factor) mobilized blood donors, respectively.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Mononuclear cell collection. | Each donor will undergo one apheresis procedure to collect mononuclear cells from their peripheral blood. |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2011-09-01
- Completion
- 2011-09-01
- First posted
- 2011-01-17
- Last updated
- 2013-05-03
- Results posted
- 2013-05-03
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01277549. Inclusion in this directory is not an endorsement.